GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together.
GSK bring deep expertise across OA biology, genetics, and statistical analysis of patient reported outcomes in OA as well as expertise in trial design and endpoint development from industry perspective.
This project is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under Grant Agreement No. 101219324.
The JU receives support from the European Union’s Horizon Europe research and innovation programme and COCIR, EFPIA, EuropaBio, MedTech Europe, Vaccines Europe, and Pacira Pharmaceuticals Inc., Capgemini Consulting, Nordic Bioscience Clinical Development A/S, and Apheris AI GmbH.
Funded by the European Union, the private members, and those contributing partners of the IHI JU. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the aforementioned parties. Neither of the aforementioned parties can be held responsible for them.
© 2026 | PROBE — Patient relevant osteoarthritis endpoints using big data evaluation
